Hepatitis B Drug Shows 20% Cure Rate in Breakthrough Trial

For the first time ever, researchers have functionally cured chronic hepatitis B in patients who participated in a groundbreaking clinical trial published in The New England Journal of Medicine this week.

Hepatitis B affects 254 million people worldwide, making it the most common liver infection on the planet. While some people clear the virus naturally, others develop a chronic infection that can lead to liver failure and death.

Until now, doctors could only suppress the virus with medication. Patients still carried the infection for life, managing it but never eliminating it.

The new study changed that equation. Nearly 2,000 patients from 29 countries received 24 weekly doses of bepirovirsen, a drug that targets hepatitis B DNA directly.

After 72 weeks, 20% of the first treatment group and 19% of the second group achieved what researchers call a "functional cure." Their bodies were free of the virus. None of the patients who received the placebo were cured.

The trial focused on patients who hadn't yet developed permanent liver scarring. Those with advanced disease weren't included, meaning the results don't apply to everyone with hepatitis B yet.

Dr. Anna Lok from the University of Michigan Medical School called the findings "a major step toward a cure" in her editorial response. She noted the results can't yet be generalized to all patient groups, particularly those with cirrhosis or liver failure.

The Bright Side

A 20% cure rate might not sound overwhelming, but it represents something monumental: proof that curing chronic hepatitis B is actually possible. For decades, doctors and patients alike believed this virus was permanently incurable once it became chronic.

GlaxoSmithKline has already applied to the FDA for approval to market bepirovirsen. The agency is expected to make its decision by October 26, 2026.

If approved, this drug could offer real hope to millions who've lived their entire lives managing an infection they thought would never leave. Even helping one in five patients represents tens of millions of potential cures worldwide.

The research also opens doors for future treatments that could work even better or help patients the current drug can't reach.

What started as an incurable diagnosis is becoming a condition where "cure" is finally part of the conversation.